Blog

Guardant360 Stories: Susan

I was like most people when I was diagnosed with cancer in July 2012 – surprised, shocked and a bit of a deer in the headlights. “NOW, what do I do?” I asked myself. I have a cancer that is difficult to treat: triple negative breast cancer (TNBC), which means my cancer does not grow […]

Read More

Liquid Biopsy Myths Dispelled

The Top 4 Liquid Biopsy Myths It is now possible to map the genomic makeup of a cancer tumor and identify personalized treatment options with just a simple blood test. Known as “liquid biopsies,” this new breed of testing decreases the need for tumor tissue biopsies that are costly, risky, and painful. It opens a […]

Read More

Time to Treatment: Guardant360 vs. The Field

In the world of advanced, metastatic cancer, time to treatment is a critical issue. Many advanced, metastatic cancer patients have failed 2‐3 lines of therapies, and time for patients and their families is growing short. Today, there are genomic tests that will sequence a patient’s tumor to identify targeted therapy options based upon the genomic […]

Read More

EGFR Mutation Stratification in First Line Treatment of Lung Adenocarcinoma

In a newly published study in The Lancet Oncology Journal, James Yang et.al. examined overall survival of EGFR mutation positive patients in lung adenocarcinoma given first-line afatinib or cisplatin-based chemotherapy.1 Although no improvement in overall survival was seen in the overall population, stratification by EGFR mutation type revealed that those with EGFR deletions in exon 19 […]

Read More